Revelation Biosciences, Inc.
REVBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Revelation Biosciences, Inc. focuses on Biotechnology services and products. Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The $2.2M market capitalization puts REVB squarely in micro-cap range for its industry. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response.
Market Cap
$2.2M
Beta
-0.06
P/E (TTM)
0.12
P/E (Fwd)
-0.19
EPS (TTM)
$32.29
EPS (Fwd)
$-20.23
ROE
-154.8%
ROA
-78.7%
Cash
$11.5M
Total Debt
$739,916
Free CF
-$5.8M
52W Change
-89.3%
Annual Financials
Cash vs Debt
Where REVB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, REVB finished 54.62% below its 150-day moving average ($7.25) and 63.89% below its 200-day moving average ($9.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is REVB overbought or oversold?
At the October 20, 2026 close, REVB's RSI(14) was 23.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Revelation Biosciences, Inc. holds $11.5M in cash against $740K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$5.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -154.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
REVB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, REVB has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing REVB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.